A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
A phase 3 trial of Capecitabine, Eribulin and Carboplatin in triple-negative breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT06279364 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 524 participants planned, started 2024-02-28 and due to reach its primary completion in 2026-07. Interventions recorded: SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Eribulin, Sichuan Kelun-Biotech, Capecitabine and the tag pipeline.
- TrialSKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shares Sichuan Kelun-Biotech, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Shares Sichuan Kelun-Biotech, Capecitabine and the tag pipeline.
- TrialSafety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Shares Eribulin, Carboplatin, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Shares Capecitabine, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Shares Eribulin, Carboplatin, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Shares Eribulin, Capecitabine and the tag pipeline.
- TrialA Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
Shares Sichuan Kelun-Biotech, Carboplatin and the tag pipeline.